{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T22:05:37Z","timestamp":1784066737714,"version":"3.55.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ard.2026.03.013","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T21:33:14Z","timestamp":1776288794000},"page":"1240-1254","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Upadacitinib vs adalimumab in patients with rheumatoid arthritis and a prior inadequate response or intolerance to a tumour necrosis factor inhibitor: 12-week results from the randomised, double-blind, SELECT-SWITCH study"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8993-0313","authenticated-orcid":false,"given":"Eduardo","family":"Mysler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prodromos I.","family":"Sidiropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andra","family":"Balanescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Detert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo M.","family":"Xavier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Charles-Schoeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Bessette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Crowley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orsolya","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanxi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingchen","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana B.","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica L.","family":"Suboticki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"DeMasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Meerwein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Fleischmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ard.2026.03.013_bib0001","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1056\/NEJMra2103726","article-title":"Rheumatoid arthritis - common origins, divergent mechanisms","volume":"388","author":"Gravallese","year":"2023","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ard.2026.03.013_bib0002","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1016\/j.immuni.2022.11.009","article-title":"McInnes IB. The pathogenesis of rheumatoid arthritis","volume":"55","author":"Alivernini","year":"2022","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.ard.2026.03.013_bib0003","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/acr.23426","article-title":"Impact of sustained remission on the risk of serious infection in patients with rheumatoid arthritis","volume":"70","author":"Accortt","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"10.1016\/j.ard.2026.03.013_bib0004","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/art.39098","article-title":"Disease activity in rheumatoid arthritis and the risk of cardiovascular events","volume":"67","author":"Solomon","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.ard.2026.03.013_bib0005","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1136\/annrheumdis-2014-206411","article-title":"The role of rheumatoid arthritis (RA) flare and cumulative burden of RA severity in the risk of cardiovascular disease","volume":"75","author":"Myasoedova","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.ard.2026.03.013_bib0006","doi-asserted-by":"crossref","first-page":"990","DOI":"10.3899\/jrheum.100935","article-title":"Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: post-hoc analysis of a randomized controlled trial","volume":"38","author":"Keystone","year":"2011","journal-title":"J Rheumatol"},{"issue":"10","key":"10.1016\/j.ard.2026.03.013_bib0007","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1007\/s10067-019-04600-7","article-title":"Long-term clinical, functional, and cost outcomes for early rheumatoid arthritis patients who did or did not achieve early remission in a real-world treat-to-target strategy","volume":"38","author":"Ten Klooster","year":"2019","journal-title":"Clin Rheumatol"},{"issue":"10055","key":"10.1016\/j.ard.2026.03.013_bib0008","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ard.2026.03.013_bib0009","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/rheumatology\/keq327","article-title":"Improvements in patient-reported outcomes, symptoms of depression and anxiety, and their association with clinical remission among patients with moderate-to-severe active early rheumatoid arthritis","volume":"50","author":"Kekow","year":"2011","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.ard.2026.03.013_bib0010","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.3899\/jrheum.161404","article-title":"Importance of obtaining remission for work productivity and activity of patients with rheumatoid arthritis","volume":"44","author":"Kim","year":"2017","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.ard.2026.03.013_bib0011","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1007\/s40744-022-00473-6","article-title":"The economic benefit of remission for patients with rheumatoid arthritis","volume":"9","author":"Curtis","year":"2022","journal-title":"Rheumatol Ther"},{"issue":"9","key":"10.1016\/j.ard.2026.03.013_bib0012","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1136\/annrheumdis-2013-203339","article-title":"Early remission is associated with improved survival in patients with inflammatory polyarthritis: results from the Norfolk Arthritis Register","volume":"73","author":"Scir\u00e8","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2026.03.013_bib0013","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.ard.2026.03.013_bib0014","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/art.41752","article-title":"2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"10.1016\/j.ard.2026.03.013_bib0015","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1007\/s10067-022-06307-8","article-title":"Predictors of remission in rheumatoid arthritis patients treated with biologics: a systematic review and meta-analysis","volume":"41","author":"Khader","year":"2022","journal-title":"Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.ard.2026.03.013_bib0016","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s10067-018-4340-7","article-title":"Remission rate and predictors of remission in patients with rheumatoid arthritis under treat-to-target strategy in real-world studies: a systematic review and meta-analysis","volume":"38","author":"Yu","year":"2019","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2026.03.013_bib0017","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s40744-025-00808-z","article-title":"Real-world analysis of initial clinical response and future outcomes among patients with rheumatoid arthritis initiating and remaining on a first-line tumor necrosis factor inhibitor in the United States","volume":"13","author":"Charles-Schoeman","year":"2026","journal-title":"Rheumatol Ther"},{"issue":"12","key":"10.1016\/j.ard.2026.03.013_bib0018","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1080\/03007995.2021.1981278","article-title":"Treatment patterns and sequencing in patients with rheumatic diseases: a retrospective claims data analysis","volume":"37","author":"Gauthier","year":"2021","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"10.1016\/j.ard.2026.03.013_bib0019","first-page":"523","article-title":"Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases","volume":"55","author":"Souto","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.ard.2026.03.013_bib0020","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s40744-017-0078-y","article-title":"Discontinuation of biologic therapy in rheumatoid arthritis: analysis from the Corrona RA Registry","volume":"4","author":"Strand","year":"2017","journal-title":"Rheumatol Ther"},{"issue":"4","key":"10.1016\/j.ard.2026.03.013_bib0021","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/acr2.11646","article-title":"Real-world treatment and care patterns in patients with rheumatoid arthritis initiating first-line tumor necrosis factor inhibitor therapy in the United States","volume":"6","author":"Edgerton","year":"2024","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.ard.2026.03.013_bib0022","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X221114101","article-title":"Managing inadequate response to initial anti-TNF therapy in rheumatoid arthritis: optimising treatment outcomes","volume":"14","author":"Taylor","year":"2022","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"10","key":"10.1016\/j.ard.2026.03.013_bib0023","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1002\/acr.24358","article-title":"Treatment sequences after discontinuing a tumor necrosis factor inhibitor in patients with rheumatoid arthritis: a comparison of cycling versus swapping strategies","volume":"73","author":"Karpes Matusevich","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"10061","key":"10.1016\/j.ard.2026.03.013_bib0024","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1016\/S0140-6736(16)31651-8","article-title":"Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ard.2026.03.013_bib0025","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1007\/s12325-017-0578-8","volume":"34","author":"Wei","year":"2017","journal-title":"Adv Ther"},{"key":"10.1016\/j.ard.2026.03.013_bib0026","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X211060910","article-title":"Comparison of long-term efficacy between biological agents following tumor necrosis factor inhibitor failure in patients with rheumatoid arthritis: a prospective cohort study","volume":"13","author":"Bogas","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"11","key":"10.1016\/j.ard.2026.03.013_bib0027","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1001\/jama.2016.13512","article-title":"Non-TNF-targeted biologic vs a second anti-TNF drug to treat rheumatoid arthritis in patients with insufficient response to a first anti-TNF drug: a randomized clinical trial","volume":"316","author":"Gottenberg","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.ard.2026.03.013_bib0028","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X211002682","article-title":"Cycling of tumor necrosis factor inhibitors versus switching to different mechanism of action therapy in rheumatoid arthritis patients with inadequate response to tumor necrosis factor inhibitors: a Bayesian network meta-analysis","volume":"13","author":"Migliore","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"5","key":"10.1016\/j.ard.2026.03.013_bib0029","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1080\/13696998.2016.1275653","article-title":"Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis","volume":"20","author":"Chastek","year":"2017","journal-title":"J Med Econ"},{"issue":"1","key":"10.1016\/j.ard.2026.03.013_bib0030","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s40744-024-00736-4","article-title":"Real-world persistence and effectiveness of upadacitinib versus other Janus kinase inhibitors and tumor necrosis factor inhibitors in Australian patients with rheumatoid arthritis","volume":"12","author":"Youssef","year":"2025","journal-title":"Rheumatol Ther"},{"issue":"9","key":"10.1016\/j.ard.2026.03.013_bib0031","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1007\/s12325-024-02948-0","article-title":"A real-world comparison of clinical effectiveness in patients with rheumatoid arthritis treated with upadacitinib, tumor necrosis factor inhibitors, and other advanced therapies after switching from an initial tumor necrosis factor inhibitor","volume":"41","author":"Caporali","year":"2024","journal-title":"Adv Ther"},{"issue":"10139","key":"10.1016\/j.ard.2026.03.013_bib0032","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","article-title":"Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Burmester","year":"2018","journal-title":"Lancet"},{"issue":"10188","key":"10.1016\/j.ard.2026.03.013_bib0033","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","article-title":"Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study","volume":"393","author":"Smolen","year":"2019","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.ard.2026.03.013_bib0034","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1056\/NEJMoa2008250","article-title":"Trial of upadacitinib or abatacept in rheumatoid arthritis","volume":"383","author":"Rubbert-Roth","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ard.2026.03.013_bib0035","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1002\/art.41384","article-title":"Efficacy and safety of upadacitinib monotherapy in methotrexate-naive patients with moderately-to-severely active rheumatoid arthritis (SELECT-EARLY): a multicenter, multi-country, randomized, double-blind, active comparator-controlled trial","volume":"72","author":"van Vollenhoven","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.ard.2026.03.013_bib0036","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003918","article-title":"Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study","volume":"10","author":"Fleischmann","year":"2024","journal-title":"RMD Open"},{"issue":"11","key":"10.1016\/j.ard.2026.03.013_bib0037","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1136\/annrheumdis-2019-215764","article-title":"Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response","volume":"78","author":"Fleischmann","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.ard.2026.03.013_bib0038","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1136\/annrheumdis-2020-218412","article-title":"Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis","volume":"80","author":"Fleischmann","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.ard.2026.03.013_bib0039","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ard.2026.03.013_bib0040","unstructured":"European Medicines Agency. Guideline on clinical investigation of medicinal products for the treatment of rheumatoid arthritis [Internet]. 2017 [cited 2025 Nov 19]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-investigation-medicinal-products-treatment-rheumatoid-arthritis_en.pdf"},{"issue":"9685","key":"10.1016\/j.ard.2026.03.013_bib0041","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0140-6736(09)60506-7","article-title":"Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial","volume":"374","author":"Smolen","year":"2009","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ard.2026.03.013_bib0042","doi-asserted-by":"crossref","first-page":"5215","DOI":"10.1007\/s12325-025-03328-y","article-title":"Safety profile of upadacitinib: descriptive analysis in over 27,000 patient-years across rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, atopic dermatitis, and inflammatory bowel disease","volume":"42","author":"Burmester","year":"2025","journal-title":"Adv Ther"},{"issue":"8","key":"10.1016\/j.ard.2026.03.013_bib0043","first-page":"1532","article-title":"Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: improvement in disability","volume":"31","author":"Baumgartner","year":"2004","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.ard.2026.03.013_bib0044","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1136\/ard.2007.071415","article-title":"Treatment-related improvement in physical function varies with duration of rheumatoid arthritis: a pooled analysis of clinical trial results","volume":"67","author":"Aletaha","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.ard.2026.03.013_bib0045","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/s41591-022-01789-0","article-title":"Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial","volume":"28","author":"Rivellese","year":"2022","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.ard.2026.03.013_bib0046","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1007\/s10067-019-04684-1","article-title":"Defining response to TNF-inhibitors in rheumatoid arthritis: the negative impact of anti-TNF cycling and the need for a personalized medicine approach to identify primary non-responders","volume":"38","author":"Johnson","year":"2019","journal-title":"Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.ard.2026.03.013_bib0047","doi-asserted-by":"crossref","first-page":"510","DOI":"10.3899\/jrheum.190102","article-title":"Toward defining primary and secondary nonresponse in rheumatoid arthritis patients treated with anti-TNF: results from the BioTRAC and OBRI registries","volume":"47","author":"Keystone","year":"2020","journal-title":"J Rheumatol"},{"issue":"7","key":"10.1016\/j.ard.2026.03.013_bib0048","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1136\/ard.2006.065615","article-title":"Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis","volume":"66","author":"Bartelds","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ard.2026.03.013_bib0049","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1136\/annrheumdis-2011-201194","article-title":"Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review","volume":"72","author":"Jamnitski","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.ard.2026.03.013_bib0050","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.ard.2025.03.015","article-title":"Adalimumab serum concentration to choose a subsequent biological DMARD in patients with rheumatoid arthritis (ADDORA-switch): results of a blinded randomised test-treatment trial","volume":"84","author":"Wientjes","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.ard.2026.03.013_bib0051","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003075","article-title":"Suboptimal management of rheumatoid arthritis in France: a real-world study based on data from the French National Health Data System","volume":"9","author":"Gaujoux-Viala","year":"2023","journal-title":"RMD Open"},{"issue":"12","key":"10.1016\/j.ard.2026.03.013_bib0052","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726001986?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726001986?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T00:04:17Z","timestamp":1783209857000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496726001986"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":52,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0003496726001986"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2026.03.013","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Upadacitinib vs adalimumab in patients with rheumatoid arthritis and a prior inadequate response or intolerance to a tumour necrosis factor inhibitor: 12-week results from the randomised, double-blind, SELECT-SWITCH study","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2026.03.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}